Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Metlife Inc. buy Barclays PLC

Start price
€57.36
17.11.23 / 50%
Target price
€65.29
17.11.24
Performance (%)
15.59%
Price
€65.82
26.04.24
Summary
This prediction is currently active. The prediction currently has a performance of 15.59%. Dividends of €0.48 are taken into consideration when calculating the performance. This prediction currently runs until 17.11.24. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this prediction

MetLife Inc. (Symbol: MET) (WKN: 934623) is a globally renowned insurance, annuities, and employee benefits company, founded in 1868, with its headquarters in New York City. As a leading player in the financial services sector, this Fortune 500 company offers a comprehensive range of products and services, including life insurance, dental and vision coverage, accident and health insurance, retirement and savings solutions, and more. Boasting a diverse clientele, MetLife serves individual customers, SMEs, and large-scale corporations across the globe, with a strong focus on enhancing value for its shareholders, policyholders, and clients. With an underlying commitment to innovation and customer-centric strategies, this publicly traded company (NYSA: MET) has established its presence in more than 40 countries, continuing to expand its horizons in the changing dynamics of global demographics and financial security needs.

Performance without dividends (%)
Name 1w 1m
Metlife Inc. -1.393% -1.393%
iShares Core DAX® 2.594% -1.158%
iShares Nasdaq 100 3.553% -1.727%
iShares Nikkei 225® 0.687% -8.354%
iShares S&P 500 2.209% -0.942%

Comments by Barclays_PLC for this prediction

In the thread Metlife Inc. diskutieren
Prediction Buy
Perf. (%) 15.59%
Target price 65.292
Change
Ends at 17.11.24

MetLife, Inc. (NYSE: MET) had its "overweight" rating re-affirmed by analysts at Barclays PLC. They now have a $71.00 price target on the stock.
Ratings data for MET provided by MarketBeat